Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats

Hypertension Research

Volumn 27, Issue 11, 2004, Pages 865-875

  Tanaka, Yasuyuki ^a   Nagai, Makoto ^a   Date, Taro ^a   Okada, Takuya ^a   Abe, Yuichi ^a   Seki, Shingo ^a   Taniguchi, Masayuki ^a   Taniguchi, Ikuo ^a   Mochizuki, Seibu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bradykinin; Cardiac fibrosis; Cardiac remodeling; Nitric oxide synthase; Renovascular hypertension

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRADYKININ; BRADYKININ B2 RECEPTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; ICATIBANT; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME RELEASE; HEART LEFT VENTRICLE WALL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; HISTOPATHOLOGY; MALE; NONHUMAN; OSMOTIC MINIPUMP; PROTEIN EXPRESSION; RAT; RENOVASCULAR HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR FIBROSIS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; BODY WEIGHT; BRADYKININ; CORONARY CIRCULATION; ECHOCARDIOGRAPHY; ENZYME INHIBITORS; FIBROSIS; HYPERTENSION, RENAL; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; ORGAN SIZE; RATS; RATS, WISTAR; RNA, MESSENGER; VENTRICULAR REMODELING;

EID: 14644396249     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.865     Document Type: Article

References (30)

1. Agabiti-Rosei E, Muiesan ML: Left ventricular hypertrophy: how to influence an important risk factor in hypertension. J Hypertens 1998; 16(Suppl 1): S53-S58.
2. Brilla CG: Renin-angiotensin system mediated mechanisms: cardioreparation and cardioprotection. Heart 2000; 84(Suppl 1): i18-i19.
3. Chin BS, Lip GY: Blockade of the renin-angiotensin-aldosterone system with combination angiotensin receptor antagonist and ACE inhibitor therapy: observations from Val-HeFT and CALM. J Hum Hypertens 2001; 15: 89-92.
4. Sadoshima J: Cytokine actions of angiotensin II. Circ Res 2000; 86: 1187-1189.
5. Remme WJ: Bradykinin-mediated cardiovascular protective actions of ACE inhibitors: a new dimension in anti-ischaemic therapy? Drugs 1997; 5(Suppl): 59-70.
6. Zuraw B: Bradykinin in protection against left-ventricular hypertrophy. Lancet 2001; 358: 1116-1168.
7. Cyr M, Eastlund T, Blais C Jr, Rouleau JL, Adam A: Bradykinin metabolism and hypotensive transfusion reactions Transfusion 2001; 41: 136-150.
8. Lauer T, Kleinbongard P, Preik M, et al: Direct biochemical evidence for eNOS stimulation by bradykinin in the human forearm vasculature. Basic Res Cardiol 2003; 98: 84-89.
9. 2 receptor knockout mice. Hypertension 2000; 35: 391-396.
10. 2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1997; 29: 478-482.
11. Hu K, Gaudron P, Anders HJ, et al: Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 1998; 39: 401-412.
12. Wang LX, Ideishi M, Yahiro E, Urata H, Arakawa K, Saku K: Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury. Hypertens Res 2001; 24: 179-187.
13. Kawabata H, Ishikawa K: Cardioprotection by metformin is abolished by a nitric oxide synthase inhibitor in ischemic rabbit hearts. Hypertens Res 2003; 26: 107-110.
14. Benetos A, Levy BI, Lacolley P, Taillard F, Duriez M, Safer ME: Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17: 3196-3201.
15. Pasquie JL, Herizi A, Jover B, Mimran A: Chronic bradykinin infusion and receptor blockade in angiotensin II hypertension in rats. Hypertension 1999; 33: 830-834.
16. Ito N, Isoyama S, Takahashi T, Takishima T: Coronary dilator reserve and morphological changes after relief of pressure-overload in rats. J Mol Cell Cardiol 1993; 25: 3-14.
17. Rhaleb NE, Yang XP, Scicli AG, Carretero OA: Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 1994; 23: 865-868.
18. Martinez-Maldonado M: Pathophysiology of renovascular hypertension. Hypertension 1991; 17: 707-719.
19. Yokota K, Kishida M, Ogura T, et al: Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension. Hypertens Res 2003; 26: 265-272.
20. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH: Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP. Hypertension 2002; 40: 498-503.
21. Wollert KC, Studer R, Doerfer K, et al: Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation 1997; 95: 1910-1917.
22. Kim NN, Villegas S, Summerour SR, Villarreal FJ: Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide. J Mol Cell Cardiol 1999; 31: 457-466.
23. Zannad F, Dousset B, Alla F: Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001; 38: 1227-1232.
24. Cheung BM, Kumana CR: Natriuretic peptides - relevance in cardiovascular disease. JAMA 1998; 280: 1983-1984.
25. 2 receptor knockout mice. Circulation 1999; 100: 2359-2365.
26. Sharma JN, Sharma J: Cardiovascular properties of the kallikrein-kinin system. Curr Med Res Opin 2002; 18: 10-17.
27. Harada S, Nakata T, Oguni A, et al: Contrasting effects of angiotensin type 1 and 2 receptors on nitric oxide release under pressure. Hypertens Res 2002; 25: 779-786.
28. Sigusch HH, Campbell SE, Weber KT: Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. Cardiovasc Res 1996; 31: 546-554.
29. Gaballa MA, Goldman S: Overexpression of endothelium nitric oxide synthase reverses the diminished vasorelaxation in the hindlimb vasculature in ischemic heart failure in vivo. J Mol Cell Cardiol 1999; 31: 1243-1252.
30. Simko F, Matuskova J, Luptak I, et al: Effect of simvastatin on the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 2004; 74: 1211-1224.